Stocks Health care STVN

NYSE · Health care

Stevanato Group S.p.A. (STVN)

Stevanato Group S.p.A. reported revenue of €1.2B in fiscal 2025, up 7.4% from a year earlier. Net income was €139.8M, a net margin of 11.8%. Operating cash flow minus capital spending left €22.3M of free cash flow in fiscal 2025. At December 31, 2025 it held €130.6M in cash against €455.1M of debt. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on March 4, 2026.

Watch STVN in 60 seconds

Follow STVN

Free, no password. An email when STVN files with the SEC.

Key facts about Stevanato Group S.p.A.

Net worth

Stevanato Group S.p.A. has a market value (market cap) of $5.8B at the latest share price, and shareholders' equity of €1.5B on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Revenue and profit

In fiscal 2025 revenue was €1.2B (+7.4% year on year), with net income of €139.8M.

Cash flow

In fiscal 2025 operations brought in €286.1M of cash; after €263.8M of capital spending, free cash flow was €22.3M.

Latest report

The latest periodic report (annual report (foreign issuer), 20-F) was filed with the SEC on March 4, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR

What Stevanato Group S.p.A. does

Stevanato Group designs and manufactures glass containment solutions and drug delivery systems for the healthcare sector. Its products include pre-fillable syringes, vials, ampoules, cartridges, and diagnostic components, as well as visual inspection and glass-forming machinery. Pharmaceutical and biotechnology companies buy its containment products to package and administer injectable drugs. Its shares trade on NYSE under the ticker STVN.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in EUR.

Key figures

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

Where STVN ranks in Health care

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Dividends

It paid out €14.7M in cash dividends, 11% of its net income.

Per share as declared (or paid, where only that is reported), adjusted for stock splits the company itself restated. Yield is the latest fiscal year's dividend over the current price.

Latest SEC filings

What Stevanato Group S.p.A. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. August 14, 2026
   Passive stake changed SCHEDULE 13G/A
2. August 13, 2026
   Passive stake (5% or more) SCHEDULE 13G
3. August 6, 2026
   Foreign issuer update 6-K
4. August 4, 2026
   Foreign issuer update 6-K
5. August 4, 2026
   Foreign issuer update 6-K
6. August 4, 2026
   Foreign issuer update 6-K
7. August 4, 2026
   Passive stake (5% or more) SCHEDULE 13G
8. June 5, 2026
   Foreign issuer update 6-K
9. May 29, 2026
   Conflict minerals disclosure SD
10. May 15, 2026
    Foreign issuer update 6-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 30, 2026. Insider transactions on SEC

Insider trades

What the people running Stevanato Group S.p.A. did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders sold $459.7K worth of shares in the last 90 days and bought none on the open market.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns STVN

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Latest filings below 5%: T. Rowe Price Investment Management, Inc. 0% (August 14, 2026); Wellington Management Group LLP 0.6% (February 10, 2025); Lazard Asset Management LLC 3.64% (November 14, 2024); Sands Capital Management, LLC 3.5% (November 14, 2024).

Largest institutional holders

Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 125 managers reported a position.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

9 insiders reported holding 635,418 shares in total, about $12.2M at the last price.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about STVN

What does Stevanato Group S.p.A. do?

Stevanato Group designs and manufactures glass containment solutions and drug delivery systems for the healthcare sector. Its products include pre-fillable syringes, vials, ampoules, cartridges, and diagnostic components, as well as visual inspection and glass-forming machinery. Pharmaceutical and biotechnology companies buy its containment products to package and administer injectable drugs. Its shares trade on NYSE under the ticker STVN.

What is Stevanato Group S.p.A.'s net worth?

Stevanato Group S.p.A. has a market value (market cap) of $5.8B at the latest share price, and shareholders' equity of €1.5B on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is Stevanato Group S.p.A. profitable?

Yes. In fiscal 2025 it reported net income of €139.8M on revenue of €1.2B, a net margin of 11.8%.

How much revenue does Stevanato Group S.p.A. make?

In fiscal 2025 Stevanato Group S.p.A. reported revenue of €1.2B. That is 7.4% more than a year earlier.

When did Stevanato Group S.p.A. last report?

Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on March 4, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the insider trade from September 30, 2026.

Theses that mention STVN

• The real bottleneck in the GLP-1 boom is not the molecules, it is glass, stoppers and injector pens Live

Similar companies

Compare STVN with

Compare STVN with any company

Follow STVN

Get an email when Stevanato Group S.p.A. files with the SEC: results, executive changes, material agreements and annual reports.

Follow STVN

Free, no password. An email when STVN files with the SEC.

Where the numbers come from

Financial figures are the values Stevanato Group S.p.A. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.